| [1] |
. Nat Med，2011，17（12）：1685?1691.
|
| [2] |
Maruoka Y，Furusawa A，Okada R，et al. Combined CD44- and CD25-targeted near-infrared photoimmunotherapy selectively kills cancer and regulatory T cells in syngeneic mouse cancer models［J］. Cancer Immunol Res，2020，8（3）：345?355.
|
| [3] |
Sato K，Nagaya T，Mitsunaga M，et al. Near infrared photoimmunotherapy for lung metastases［J］. Cancer Lett，2015，365（1）：112?121.
|
| [4] |
Sato K，Nagaya T，Nakamura Y，et al. Near infrared photoimmunotherapy prevents lung cancer metastases in a murine model［J］. Oncotarget，2015，6（23）：19747?19758.
|
| [5] |
Kobayashi H，Choyke PL. Near-infrared photoimmunotherapy of cancer［J］. Acc Chem Res，2019，52（8）：2332?2339.
|
| [6] |
Zheng L，Tan W，Zhang J，et al. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling［J］. Cancer Immunol Immunother，2014，63（6）：581?586.
|
| [7] |
Boeckx C，Blockx L，de Beeck KO，et al. Establishment and characterization of cetuximab resistant head and neck squamous cell carcinoma cell lines：focus on the contribution of the AP-1 transcription factor［J］. Am J Cancer Res，2015，5（6）：1921?1938.
|
| [8] |
Sano K，Nakajima T，Choyke PL，et al. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors［J］. ACS Nano，2013，7（1）：717?724.
|
| [9] |
Burley TA，Maczynska J，Shah A，et al. Near-infrared photoimmunotherapy targeting EGFR-shedding new light on glioblastoma treatment［J］. Int J Cancer，2018，142（11）：2363?2374.
|
| [10] |
Nishimura T，Mitsunaga M，Sawada R，et al. Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody［J］. Cancer Med，2019，8（18）：7781?7792.
|
| [11] |
Kiss B，van den Berg NS，Ertsey R，et al. CD47-targeted near-infrared photoimmunotherapy for human bladder cancer［J］. Clin Cancer Res，2019，25（12）：3561?3571.
|
| [12] |
Wei W，Jiang D，Ehlerding EB，et al. CD146-targeted multimodal image-guided photoimmunotherapy of melanoma［J］. Adv Sci （Weinh），2019，6（9）：1801237.
|
| [13] |
Isobe Y，Sato K，Nishinaga Y，et al. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer［J］. EBioMedicine，2020，52：102632.
|
| [14] |
Sato K，Hanaoka H，Watanabe R，et al. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer［J］. Mol Cancer Ther，2015，14（1）：141?150.
|
| [15] |
Nagaya T，Okuyama S，Ogata F，et al. Near infrared photoimmunotherapy using a fiber optic diffuser for treating peritoneal gastric cancer dissemination［J］. Gastric Cancer，2019，22（3）：463?472.
|
| [16] |
Nagaya T，Okuyama S，Ogata F，et al. Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor （EGFR） antibody［J］. Oncotarget，2018，9（27）：19026?19038.
|
| [17] |
Kobayashi H，Griffiths GL，Choyke PL. Near-infrared photoimmunotherapy：photoactivatable antibody-drug conjugates （ADCs） ［J］. Bioconjug Chem，2020，31（1）：28?36.
|
| [18] |
Li F，Zhao Y，Mao C，et al. RGD-modified albumin nanoconjugates for targeted delivery of a porphyrin photosensitizer［J］. Mol Pharm，2017，14（8）：2793?2804.
|
| [19] |
Perez HL，Cardarelli PM，Deshpande S，et al. Antibody-drug conjugates：current status and future directions［J］. Drug Discov Today，2014，19（7）：869?881.
|
| [20] |
Amoury M，Bauerschlag D，Zeppernick F，et al. Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand［J］. Oncotarget，2016，7（34）：54925?54936.
|
| [21] |
Okuyama S，Nagaya T，Sato K，et al. Interstitial near-infrared photoimmunotherapy：effective treatment areas and light doses needed for use with fiber optic diffusers［J］. Oncotarget，2018，9（13）：11159?11169.
|
| [22] |
Nakajima T，Sato K，Hanaoka H，et al. The effects of conjugate and light dose on photo-immunotherapy induced cytotoxicity［J］. BMC Cancer，2014，14：389.
|
| [23] |
Sato K，Watanabe R，Hanaoka H，et al. Comparative effectiveness of light emitting diodes （LEDs） and lasers in near infrared photoimmunotherapy［J］. Oncotarget，2016，7（12）：14324?14335.
|
| [24] |
Peng W，de Bruijn HS，Farrell E，et al. Epidermal growth factor receptor （EGFR） density may not be the only determinant for the efficacy of EGFR-targeted photoimmunotherapy in human head and neck cancer cell lines［J］. Lasers Surg Med，2018，50（5）：513?522.
|
| [25] |
Nagaya T，Sato K，Harada T，et al. Near infrared photoimmunotherapy targeting EGFR positive triple negative breast cancer：optimizing the conjugate-light regimen［J］. PLoS One，2015，10（8）：e0136829.
|
| [26] |
Kishimoto S，Bernardo M，Saito K，et al. Evaluation of oxygen dependence on in vitro and in vivo cytotoxicity of photoimmunotherapy using IR-700-antibody conjugates［J］. Free Radic Biol Med，2015，85：24?32.
|
| [27] |
van Lith SAM，van den Brand D，Wallbrecher R，et al. The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates［J］. Eur J Pharm Biopharm，2018，124：63?72.
|
| [28] |
Mao C，Zhao Y，Li F，et al. P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors［J］. J Control Release，2018，286：289?300.
|
| [29] |
Nakamura Y，Nagaya T，Sato K，et al. Alterations of filopodia by near infrared photoimmunotherapy：evaluation with 3D low-coherent quantitative phase microscopy［J］. Biomed Opt Express，2016，7（7）：2738?2748.
|
| [30] |
Sano K，Mitsunaga M，Nakajima T，et al. Acute cytotoxic effects of photoimmunotherapy assessed by 18F-FDG PET［J］. J Nucl Med，2013，54（5）：770?775.
|
| [31] |
Ogata F，Nagaya T，Okuyama S，et al. Dynamic changes in the cell membrane on three dimensional low coherent quantitative phase microscopy （3D LC-QPM） after treatment with the near infrared photoimmunotherapy［J］. Oncotarget，2017，8（61）：104295?104302.
|
| [32] |
Nakajima K，Takakura H，Shimizu Y，et al. Changes in plasma membrane damage inducing cell death after treatment with near-infrared photoimmunotherapy［J］. Cancer Sci，2018，109（9）：2889?2896.
|
| [33] |
Sato K，Watanabe R，Hanaoka H，et al. Photoimmunotherapy：comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor［J］. Mol Oncol，2014，8（3）：620?632.
|
| [34] |
Sato K，Choyke PL，Kobayashi H. Photoimmunotherapy of gastric cancer peritoneal carcinomatosis in a mouse model［J］. PLoS One，2014，9（11）：e113276.
|
| [35] |
Kishimoto S，Oshima N，Yamamoto K，et al. Molecular imaging of tumor photoimmunotherapy：evidence of photosensitized tumor necrosis and hemodynamic changes［J］. Free Radic Biol Med，2018，116：1?10.
|
| [36] |
Sato K，Ando K，Okuyama S，et al. Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies：a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy［J］. ACS Cent Sci，2018，4（11）：1559?1569.
|
| [37] |
Dong H，Wu R，Liu J，et al. Advances in cancer photodynamic therapy［J］. J China Pharm Univ（中国药科大学学报），2016，47（4）：377?387.
|
| [38] |
Isoda Y，Piao W，Taguchi E，et al. Development and evaluation of a novel antibody-photon absorber conjugate reveals the possibility of photoimmunotherapy-induced vascular occlusion during treatment in vivo［J］. Oncotarget，2018，9（59）：31422?31431.
|
| [39] |
Nagaya T，Okuyama S，Ogata F，et al. Endoscopic near infrared photoimmunotherapy using a fiber optic diffuser for peritoneal dissemination of gastric cancer［J］. Cancer Sci，2018，109（6）：1902?1908.
|
| [40] |
Maruoka Y，Nagaya T，Sato K，et al. Near infrared photoimmunotherapy with combined exposure of external and interstitial light sources［J］. Mol Pharm，2018，15（9）：3634?3641.
|
| [41] |
Nakajima K，Kimura T，Takakura H，et al. Implantable wireless powered light emitting diode （LED） for near-infrared photoimmunotherapy：device development and experimental assessment in vitro and in vivo［J］. Oncotarget，2018，9（28）：20048?20057.
|
| [42] |
Mitsunaga M，Nakajima T，Sano K，et al. Near-infrared theranostic photoimmunotherapy （PIT）：repeated exposure of light enhances the effect of immunoconjugate［J］. Bioconjug Chem，2012，23（3）：604?609.
|
| [43] |
Mitsunaga M，Nakajima T，Sano K，et al. Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy［J］. BMC Cancer，2012，12：345.
|
| [44] |
Okuyama S，Nagaya T，Ogata F，et al. Avoiding thermal injury during near-infrared photoimmunotherapy （NIR-PIT）：the importance of NIR light power density［J］. Oncotarget，2017，8（68）：113194?113201.
|
| [45] |
Nakajima T，Sano K，Mitsunaga M，et al. Real-time monitoring of in vivo acute necrotic cancer cell death induced by near infrared photoimmunotherapy using fluorescence lifetime imaging［J］. Cancer Res，2012，72（18）：4622?4628.
|
| [46] |
Maruoka Y，Nagaya T，Nakamura Y，et al. Evaluation of early therapeutic effects after near-infrared photoimmunotherapy （NIR-PIT） using luciferase-luciferin photon-counting and fluorescence imaging［J］. Mol Pharm，2017，14（12）：4628?4635.
|
百度学术
下载:
